The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Pharmacyclics Inc

Nasdaq: PCYC
Last

(U.S.) $261.25

Today's change+1.70 +0.65%
Updated May 22 4:00 PM EDT. Delayed by at least 15 minutes.
 

Pharmacyclics Inc

Nasdaq: PCYC
Last

(U.S.) $261.25

Today's change+1.70 +0.65%
Updated May 22 4:00 PM EDT. Delayed by at least 15 minutes.

Pharmacyclics Inc Hits New 52-week High

Pharmacyclics Inc closed up Friday by (U.S.)$1.70 or 0.65% to (U.S.)$261.25 and setting a new 52-week high. Over the last five days, shares have gained 2.28% and 113.68% year to date. Shares have outperformed the S&P 500 by 163.92% during the last year.

Key company metrics

  • Open(U.S.) $260.76
  • Previous close(U.S.) $259.55
  • High(U.S.) $261.68
  • Low(U.S.) $260.76
  • Bid / Ask-- / --
  • YTD % change+113.68%
  • Volume1,953,837
  • Average volume (10-day)854,802
  • Average volume (1-month)753,858
  • Average volume (3-month)1,508,037
  • 52-week range(U.S.) $82.51 to (U.S.) $261.68
  • Beta0.52
  • Trailing P/E292.03×
  • P/E 1 year forward538.66×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $0.89
Updated May 22 4:00 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+8.82%

Based on its net profit margin of 8.82%, Pharmacyclics Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.02%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue206290207113
Total other revenue--------
Total revenue206290207113
Gross profit189277196104
Total cost of revenue1713129
Total operating expense202197159150
Selling / general / administrative50503845
Research & development49484446
Depreciation / amortization0000
Interest expense (income), net operating--------
Unusual expense (income)86866550
Other operating expenses, total--00--
Operating income49348-37
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax49348-37
Income after tax46341-37
Income tax, total03070
Net income46341-37
Total adjustments to net income--------
Net income before extra. items46341-37
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items46341-37
Inc. avail. to common incl. extra. items46341-37
Diluted net income46341-37
Dilution adjustment------0
Diluted weighted average shares79797875
Diluted EPS excluding extraordinary itemsvalue per share0.050.810.53-0.49
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share1.121.551.24-0.06